AR072189A1 - Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio. - Google Patents
Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio.Info
- Publication number
- AR072189A1 AR072189A1 ARP090102225A ARP090102225A AR072189A1 AR 072189 A1 AR072189 A1 AR 072189A1 AR P090102225 A ARP090102225 A AR P090102225A AR P090102225 A ARP090102225 A AR P090102225A AR 072189 A1 AR072189 A1 AR 072189A1
- Authority
- AR
- Argentina
- Prior art keywords
- moduladores
- adrenoreceptores
- oxazinones
- benzo
- beta
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 abstract 1
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7342008P | 2008-06-18 | 2008-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072189A1 true AR072189A1 (es) | 2010-08-11 |
Family
ID=41434296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102225A AR072189A1 (es) | 2008-06-18 | 2009-06-18 | Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8017602B2 (enExample) |
| EP (1) | EP2303873A4 (enExample) |
| JP (1) | JP2011524896A (enExample) |
| KR (1) | KR20110017456A (enExample) |
| CN (1) | CN102124003A (enExample) |
| AR (1) | AR072189A1 (enExample) |
| AU (1) | AU2009260899B2 (enExample) |
| BR (1) | BRPI0915428A2 (enExample) |
| CA (1) | CA2726746A1 (enExample) |
| CL (1) | CL2010001459A1 (enExample) |
| CO (1) | CO6321269A2 (enExample) |
| CR (1) | CR11856A (enExample) |
| DO (1) | DOP2010000389A (enExample) |
| EA (1) | EA201001747A1 (enExample) |
| EC (1) | ECSP10010694A (enExample) |
| IL (1) | IL209731A0 (enExample) |
| MX (1) | MX2010013477A (enExample) |
| TW (1) | TW201002696A (enExample) |
| UY (1) | UY31905A (enExample) |
| WO (1) | WO2009154557A1 (enExample) |
| ZA (1) | ZA201008886B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011524896A (ja) | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| CN102993116A (zh) * | 2012-12-04 | 2013-03-27 | 常州大学 | 一种苯并噁嗪类激动剂的制备方法 |
| ME03316B (me) * | 2014-06-30 | 2019-10-20 | Astrazeneca Ab | Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora |
| CN104496920A (zh) * | 2014-12-04 | 2015-04-08 | 北京理工大学 | 一种n-烯丙基-二取代四唑及其制备方法和检测方法 |
| CN107188865B (zh) * | 2016-03-14 | 2019-08-27 | 益方生物科技（上海）有限公司 | 苯并噁嗪化合物及其制备方法和用途 |
| PL424609A1 (pl) * | 2018-02-16 | 2019-08-26 | Uniwersytet Przyrodniczy we Wrocławiu | Zastosowanie 6-(tert-butylo)-3-dodecylo-3,4-dihydro-2H-benzo[e][1,3]oxazyny |
| CN110028521B (zh) * | 2019-05-27 | 2020-07-14 | 湖南科技大学 | 11-芳基-1,4-苯并恶嗪酮并咪唑啉类化合物及其制备方法和用途 |
| EP4194453A1 (en) | 2021-12-08 | 2023-06-14 | Basf Se | Pyrazine compounds for the control of invertebrate pests |
| WO2023104564A1 (en) | 2021-12-08 | 2023-06-15 | Basf Se | Pyrazine compounds for the control of invertebrate pests |
| CN117143019B (zh) * | 2023-07-28 | 2025-11-25 | 常州大学 | 用作β2-肾上腺素受体别构拮抗剂的吡唑酰胺类衍生物 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2653977A (en) | 1953-09-29 | Chxnx | ||
| US3775477A (en) | 1971-03-10 | 1973-11-27 | Sterling Drug Inc | N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides |
| US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| DE3571808D1 (en) | 1984-04-17 | 1989-08-31 | Glaxo Group Ltd | Ethanolamine compounds |
| US4554284A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
| US4554287A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
| GB8525483D0 (en) | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
| GB8718938D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
| JPH03133946A (ja) | 1989-10-10 | 1991-06-07 | Glaxo Group Ltd | フェンエタノールアミン化合物 |
| IE914003A1 (en) | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
| US5648370A (en) | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
| GB9210632D0 (en) | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| GB9211172D0 (en) | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
| TW356468B (en) | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
| GB9526511D0 (en) | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
| EP0914319B1 (en) | 1996-05-20 | 2001-11-21 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
| SE9700706D0 (sv) | 1997-02-27 | 1997-02-27 | Astra Pharma Prod | Process for the preparation of benzothiazoline compounds |
| SE9701304D0 (sv) | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
| US20020010197A1 (en) | 1998-01-13 | 2002-01-24 | John Dixon | Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902936D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902937D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902938D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| WO2005110990A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| EP1751086A2 (en) | 2004-06-03 | 2007-02-14 | Theravance, Inc. | DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS |
| JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| EP1786762A2 (en) | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EA200701260A1 (ru) | 2005-01-11 | 2008-02-28 | Глаксо Груп Лимитед | Циннаматные соли бета-2 адренергического агониста |
| GB0511066D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| NZ585580A (en) | 2005-07-18 | 2011-08-26 | Pfizer Ltd | Process for the preparation of sulfonamide derivatives |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745084A (en) * | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2008041914A1 (en) | 2006-10-06 | 2008-04-10 | Astrazeneca Ab | 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS |
| US20120142646A1 (en) | 2006-12-20 | 2012-06-07 | Lilian Alcaraz | Novel Compounds 621 |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0702459D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 669 |
| GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
| GB0704000D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| JP2011524896A (ja) | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
| WO2009154562A1 (en) | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
-
2009
- 2009-06-17 JP JP2011514537A patent/JP2011524896A/ja active Pending
- 2009-06-17 EP EP09766947A patent/EP2303873A4/en not_active Withdrawn
- 2009-06-17 AU AU2009260899A patent/AU2009260899B2/en not_active Ceased
- 2009-06-17 BR BRPI0915428A patent/BRPI0915428A2/pt not_active IP Right Cessation
- 2009-06-17 WO PCT/SE2009/050749 patent/WO2009154557A1/en not_active Ceased
- 2009-06-17 KR KR1020117001144A patent/KR20110017456A/ko not_active Withdrawn
- 2009-06-17 UY UY0001031905A patent/UY31905A/es unknown
- 2009-06-17 EA EA201001747A patent/EA201001747A1/ru unknown
- 2009-06-17 MX MX2010013477A patent/MX2010013477A/es active IP Right Grant
- 2009-06-17 TW TW098120291A patent/TW201002696A/zh unknown
- 2009-06-17 CA CA2726746A patent/CA2726746A1/en not_active Abandoned
- 2009-06-17 CN CN2009801320729A patent/CN102124003A/zh active Pending
- 2009-06-18 AR ARP090102225A patent/AR072189A1/es unknown
- 2009-06-18 US US12/486,854 patent/US8017602B2/en not_active Expired - Fee Related
-
2010
- 2010-11-29 CO CO10150418A patent/CO6321269A2/es not_active Application Discontinuation
- 2010-12-02 IL IL209731A patent/IL209731A0/en unknown
- 2010-12-09 ZA ZA2010/08886A patent/ZA201008886B/en unknown
- 2010-12-17 DO DO2010000389A patent/DOP2010000389A/es unknown
- 2010-12-17 EC EC2010010694A patent/ECSP10010694A/es unknown
- 2010-12-17 CL CL2010001459A patent/CL2010001459A1/es unknown
- 2010-12-17 CR CR11856A patent/CR11856A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CR11856A (es) | 2011-02-25 |
| IL209731A0 (en) | 2011-02-28 |
| MX2010013477A (es) | 2010-12-21 |
| WO2009154557A1 (en) | 2009-12-23 |
| CL2010001459A1 (es) | 2011-09-23 |
| EP2303873A4 (en) | 2012-01-04 |
| AU2009260899B2 (en) | 2012-02-23 |
| US8017602B2 (en) | 2011-09-13 |
| KR20110017456A (ko) | 2011-02-21 |
| EP2303873A1 (en) | 2011-04-06 |
| DOP2010000389A (es) | 2011-01-15 |
| ECSP10010694A (es) | 2011-01-31 |
| AU2009260899A1 (en) | 2009-12-23 |
| CA2726746A1 (en) | 2009-12-23 |
| ZA201008886B (en) | 2011-08-31 |
| JP2011524896A (ja) | 2011-09-08 |
| US20100105642A1 (en) | 2010-04-29 |
| BRPI0915428A2 (pt) | 2015-11-03 |
| CO6321269A2 (es) | 2011-09-20 |
| TW201002696A (en) | 2010-01-16 |
| CN102124003A (zh) | 2011-07-13 |
| EA201001747A1 (ru) | 2011-08-30 |
| UY31905A (es) | 2010-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20080827A1 (es) | N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2 | |
| AR070517A1 (es) | Piperidinas inhibidoras de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
| AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
| CO6321269A2 (es) | Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR064258A1 (es) | Inhibidores macrociclicos del virus de hepatitis c | |
| AR060591A1 (es) | Compuestos imidazo | |
| PE20140934A1 (es) | Derivados de pirazol | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| PE20080378A1 (es) | Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa | |
| AR074352A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica. | |
| PE20081227A1 (es) | Derivados indazolil sulfonamidas como moduladores de glucocorticoides | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| PE20070712A1 (es) | Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |